A Study of Early Secukinumab Treatment in Moderate to Severe Hidradenitis Suppurativa Patients

NCT07690319 · clinicaltrials.gov ↗
NOT_YET_RECRUITING
Status
186
Enrollment
INDUSTRY
Sponsor class

Conditions

Sponsor

Novartis Pharmaceuticals